Home › Non-Small Cell Lung Cancer › Nevada › Reno
Pag-aaral pangklinika para sa Non-Small Cell Lung Cancer sa Reno, NV
16 pag-aaral para sa Non-Small Cell Lung Cancer ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Reno (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Nagre-recruitPhase 2
- Renown Regional Medical Center /ID# 273535, Reno
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Nagre-recruitPhase 3
- Gene Upshaw Memorial Tahoe Forest Cancer Center, Truckee · 24 mi ang layo
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Nagre-recruitPhase 3
- Renown Regional Medical Center-Renown Health Medical Oncology ( Site 3207), Reno
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Nagre-recruitPhase 3
- Renown Health Medical Oncology, Reno
- Renown Office of Clinical Research, Reno
- Renown Regional Medical Center, Reno
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Nagre-recruitPhase 3
- Renown Regional Medical Center-Renown Health Medical Oncology ( Site 0037), Reno
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Nagre-recruitPhase 3
- Renown Regional Medical Center-Renown Health Medical Oncology ( Site 0134), Reno
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Nagre-recruitPhase 3
- Research Site, Reno
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Nagre-recruitPhase 3
- Renown Regional Medical Center, Reno
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Nagre-recruitPhase 2/3
- Renown Regional Medical Center, Reno
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Nagre-recruitPhase 3
- Cancer Care Specialists, Reno
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Nagre-recruitPhase 3
- Renown Regional Medical Center, Reno
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
Nagre-recruitPhase 3
- Cancer Care Specialists, Reno
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Nagre-recruitPhase 3
- Cancer Care Specialists, Reno
Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer
Nagre-recruitPhase 2
- Tahoe Forest Cancer Center, Truckee · 24 mi ang layo
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Nagre-recruitPhase 2/3
- Gene Upshaw Memorial Tahoe Forest Cancer Center, Truckee · 24 mi ang layo
GEMINI-NSCLC: NSCLC Biomarker Study
Nagre-recruitObservasyonal na pag-aaral
- Cancer Care Specialists Reno, Reno
Pag-aaral para sa Non-Small Cell Lung Cancer sa ibang lungsod
- Houston, TX145 pag-aaral
- New York City, NY121 pag-aaral
- Arlington, VA104 pag-aaral
- Nashville, TN97 pag-aaral
- Boston, MA90 pag-aaral
- Los Angeles, CA87 pag-aaral
- St. Louis, MO73 pag-aaral
- Chicago, IL61 pag-aaral
- Baltimore, MD60 pag-aaral
- San Antonio, TX59 pag-aaral
- Columbus, OH57 pag-aaral
- Washington, DC55 pag-aaral
Iba pang pag-aaral sa Reno
- Kanser sa Suso13 pag-aaral
- Kanser sa Baga9 pag-aaral
- Degenerasyon ng Macula8 pag-aaral
- Geographic Atrophy8 pag-aaral
- Kanser sa Ovary7 pag-aaral
- Kanser (lahat ng uri)7 pag-aaral
- Acute Myeloid Leukemia5 pag-aaral
- Kanser sa Pancreas5 pag-aaral
- Metastatic Cancer5 pag-aaral
- Colon Cancer5 pag-aaral
- Colorectal Cancer5 pag-aaral
- Rectal Cancer4 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.